Schizophrenia

The Challenges of Identifying Biomarkers of Psychiatric Illness

The Challenges of Identifying Biomarkers of Psychiatric Illness

By

There is minimal overlap in neurologic variations among individuals with severe psychiatric conditions such as schizophrenia spectrum disorders and bipolar disorder.

Pathways for Intellectual Disability in Children: Maternal Mental Illness vs Obstetric Complications

Pathways for Intellectual Disability in Children: Maternal Mental Illness vs Obstetric Complications

By

Investigators sought to determine the relationship between familial severe mental illness vs obstetric complications and the risk for developing intellectual disability

Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia

Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia

By

Investigators sought to determine whether cardioprotective medication after a myocardial infarction could reduce mortality rates in patients with schizophrenia.

Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive Dyskinesia

Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive Dyskinesia

By

These results provide support for switching antipsychotics to clozapine in patients with moderate to severe tardive dyskinesia.

Long-term Treatment Outcomes With Aripiprazole Lauroxil in Schizophrenia

Long-term Treatment Outcomes With Aripiprazole Lauroxil in Schizophrenia

By

Safety, symptoms, and illness trajectory of outpatients with schizophrenia who received ongoing aripiprazole lauroxil were followed for 2 years.

Increased Adherence With Paliperidone Once Every 3 Months in Schizophrenia

Increased Adherence With Paliperidone Once Every 3 Months in Schizophrenia

By

Transition from a once-monthly formulation of a long-acting, injectable paliperidone palmitate to a once-every-3-month formulation treatment regimen in patients with schizophrenia demonstrated increased adherence to antipsychotic medication.

Brexpiprazole Appears Safe, Effective in Schizophrenia During Severe Psychotic Episodes

Brexpiprazole Appears Safe, Effective in Schizophrenia During Severe Psychotic Episodes

By

At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.

Latent Structure of Negative Symptoms in Schizophrenia Best Conceptualized by 5-Domain Model

Latent Structure of Negative Symptoms in Schizophrenia Best Conceptualized by 5-Domain Model

By

Existing 2-dimensional models are likely not sufficient to capture the complexity of negative symptoms in schizophrenia.

Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia

Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia

By

Interventions focused on emotion recognition may be effective in addressing sociocognitive deficits in patients with schizophrenia.

First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes

First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes

By

A team of UK-based investigators assessed functional and symptomatic outcomes in individuals with a first episode of psychotic disorder vs those associated with schizophrenia.

Prevalence of Schizophrenia in Individuals With Type 2 Diabetes

Prevalence of Schizophrenia in Individuals With Type 2 Diabetes

By

In an attempt to identify the risk associated with the comorbidity of type 2 diabetes and schizophrenia, a team of investigators from Taiwan assessed the impact of public health promotion efforts targeted at this population.

Metabolic Syndrome Predictive of Psychotic Relapse in Schizophrenia

Metabolic Syndrome Predictive of Psychotic Relapse in Schizophrenia

By

This research supports the monitoring of metabolic syndrome in patients with schizophrenia.

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

By

Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.

Moving Associated With Increased Risk for Psychosis in Children, Adolescents

Moving Associated With Increased Risk for Psychosis in Children, Adolescents

By

These data suggest that residential mobility may have a profound effect on the mental well-being of children and adolescents.

Clinical Markers Predict Resistance to Antipsychotic Therapy in Schizophrenia

Clinical Markers Predict Resistance to Antipsychotic Therapy in Schizophrenia

By

Timely categorization of patients as treatment-resistant or responsive may allow faster implementation of better targeted interventions.

Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations

Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations

By

In conclusion, these preliminary findings suggest that quetiapine is not a teratogen and could be used safely during pregnancy, but further research is needed to completely understand the risks involved.

Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia

Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia

By

Future studies should investigate how supplementation with vitamin D may improve symptoms and outcomes.

Using Neurocognitive Profiles to Predict Conversion to Psychosis in High-Risk Patients

Using Neurocognitive Profiles to Predict Conversion to Psychosis in High-Risk Patients

By

The study exhibited an overall conversion rate of 35% to a psychotic disorder.

Remission of Schizophrenia Seen With Amisulpride, Clozapine

Remission of Schizophrenia Seen With Amisulpride, Clozapine

Remission can be achieved for most cases of schizophrenia and schizophreniform disorder with amisulpride and clozapine.

Symptoms of Sleep Disorders Prevalent in Psychiatric Illnesses

Symptoms of Sleep Disorders Prevalent in Psychiatric Illnesses

By

The authors argue that identifying and treating sleep disorders during early stages may have a positive impact on outcomes in psychiatric patients.

Reducing Off-Label Quetiapine Prescribing the Old-Fashioned Way: Snail Mail

Reducing Off-Label Quetiapine Prescribing the Old-Fashioned Way: Snail Mail

By

Despite the associated risk for death and cognitive decline, "off-label" prescribing of antipsychotics in patients with dementia has increased.

Dose-Response Relationship Observed Between CBT, Reduction in Schizophrenia Symptoms

Dose-Response Relationship Observed Between CBT, Reduction in Schizophrenia Symptoms

By

The dose-response relationship observed between CBT and schizophrenia outcome may be salient to clinicians in titrating treatment strategies.

Hyperprolactinemia and Insulin Resistance Associated With First-Episode Psychosis

Hyperprolactinemia and Insulin Resistance Associated With First-Episode Psychosis

By

There was a significantly higher level of prolactin found in the first episode psychosis group than in the clinical high risk group, suggesting a condition of hyperprolactinemia.

First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide

First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide

By

Researchers found a suicide attempt rate of 12.0% in first-episode, drug-naive inpatients.

Second Generation Long-Acting Injectable Drugs Effective for Schizophrenia

Second Generation Long-Acting Injectable Drugs Effective for Schizophrenia

By

The findings support second generation long-acting injectable antipsychotic drug use as early treatment option to increase treatment adherence and to decrease the risk of relapse, hospitalization, and deteriorating social functions.

Potential Utility of Adjunctive <i>Withania somnifera</i> in Schizophrenia Treatment

Potential Utility of Adjunctive Withania somnifera in Schizophrenia Treatment

By

WSE treatment may be useful in addressing symptom exacerbation in schizophrenia and schizoaffective disorder.

Social Functioning, Treatment With Antipsychotic Agents Associated With Employment in Schizophrenia

Social Functioning, Treatment With Antipsychotic Agents Associated With Employment in Schizophrenia

By

Investigators examined factors that may improve employment in patients with schizophrenia.

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

By

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

Antipsychotic Medication May Affect HDL-Cholesterol Levels for Some Patients With Schizophrenia

Antipsychotic Medication May Affect HDL-Cholesterol Levels for Some Patients With Schizophrenia

By

These results may be helpful for clinicians when considering the effects of antipsychotic intervention on patient high-density lipoprotein cholesterol levels.

Adolescent Inhalant Use Associated With Higher Risk for Psychosis

Adolescent Inhalant Use Associated With Higher Risk for Psychosis

By

Inhalant and other substance use during adolescence are increasingly associated with many adverse health and psychosocial outcomes.

Sign Up for Free e-newsletters